This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Xarelto
  • /
  • Rivaroxaban for the Prevention of Major Cardiovasc...
Clinical trial

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

Read time: 3 mins
Last updated:1st Feb 2013
Identifier: NCT01776424

The primary purpose of this study is to evaluate whether treatment with rivaroxaban and aspirin or rivaroxaban alone is better than aspirin alone in prevention of heart attacks, stroke or cardiovascular death in patients with coronary or peripheral artery disease.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).
Enrollment: 27395
Actual Study Start Date: February 28, 2013
Estimated Study Completion Date: March 31, 2018
Primary Completion Date: July 21, 2017 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Rivaroxaban [2.5mg] + Aspirin
- Experimental: Rivaroxaban [5mg] + Placebo(1)
- Active Comparator: Aspirin + Placebo(2)


Related journal:
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Category Value
Date last updated at source 2017-09-26
Study type(s) Interventional
Expected enrolment 27395
Study start date 2013-02-01
Estimated primary completion date 2017-07-21

View full details